Description: Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various types of solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was founded in 2016 and is headquartered in London, the United Kingdom.
Home Page: www.achillestx.com
ACHL Technical Analysis
245 Hammersmith Road
London,
W6 8PW
United Kingdom
Phone:
44 20 8154 4600
Officers
| Name | Title |
|---|---|
| Dr. Iraj Ali | CEO & Director |
| Dr. Karl Peggs M.D. | Founder & Chief Medical Officer |
| Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D. | Founder |
| Dr. Charles Swanton FMEDSCI, M.D., Ph.D. | Founder |
| Dr. Sergio A. Quezada Ph.D. | Founder & Chief Scientific Officer |
| Mr. Robert Coutts | Chief Financial Officer |
| Mr. Lee M. Stern | VP of Investor Relations & External Communications |
| Mr. Daniel Hood | Gen. Counsel & Company Sec. |
| Julia Wilson | Head of Communications |
| Mr. Tariq Ahmed | VP of People |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0.1858 |
| Price-to-Book MRQ: | 0.2627 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-03-31 |
| Fiscal Year End: | December |
| Full Time Employees: | 242 |